Method for constructing anti-PRRSV gene editing pig based on CRISPR / Cas9 homologous recombination

By precisely knocking out the Ala-His-Phe-Gly-Gly receptor-binding pentad in the porcine CD163 gene using CRISPR/Cas9 homologous recombination technology, the inaccuracy and loss of function in CD163 gene editing in existing technologies have been solved. This has achieved effective resistance to PRRSV and preservation of normal CD163 function, thereby improving the survival rate and health status of gene-edited pigs.

CN121202964APending Publication Date: 2025-12-26SOUTH CHINA AGRICULTURAL UNIVERSITY
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202511774200.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-11-28
Publication Date
2025-12-26

AI Technical Summary

Technical Problem

Existing CRISPR/Cas9 gene editing technology struggles to achieve precise editing when knocking out the CD163 gene in pigs. This leads to increased resistance to PRRSV, but also results in the loss of normal physiological function of CD163, increasing the risk of inflammatory responses and secondary infections. Furthermore, existing strategies may potentially damage genome stability.

Method used

Using CRISPR/Cas9 homologous recombination technology, we designed specific sgRNAs and homologous repair templates targeting the CD163 SRCR5 domain, precisely knocked out the Ala-His-Phe-Gly-Glu receptor-binding pentad in the CD163 protein, and preserved the scavenger function of CD163 through homologous recombination, reducing genomic damage and toxic side effects.

Benefits of technology

It achieved effective resistance to PRRSV while maintaining the normal biological function of CD163, reduced the risk of secondary infection and genomic damage, improved the survival rate and health status of gene-edited pigs, and provided reliable breeding material.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121202964A_ABST
    Figure CN121202964A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of animal genetic engineering and animal breeding, in particular to a method for constructing an anti-PRRSV pig based on CRISPR / Cas9 homologous recombination. According to the invention, specific sgRNA and a homologous repair template are designed aiming at the receptor-bound pentasaccharide in an SRCR5 structural domain of a pig CD163 gene, accurate knockout of the receptor-bound pentasaccharide is realized in fibroblast of a pig fetus, homozygous deletion cell clone is obtained, and then the receptor-bound pentasaccharide knockout pig is prepared through a somatic cell nuclear transplantation (SCNT) technology. Compared with a wild control pig, the gene editing pig prepared by the invention has obvious disease resistance to the JXA1 strain and is normal in growth and development. The CD163 scavenger receptor function is reserved to the maximum extent, potential side effects are reduced, and a new breeding material capable of being directly used for resisting PRRSV is provided for the live pig industry.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present application relates to the field of animal genetic engineering and animal breeding technology, and particularly relates to a method for constructing a PRRSV-resistant gene-edited pig based on CRISPR / Cas9 homologous recombination. BACKGROUND

[0002] Porcine reproductive and respiratory syndrome (PRRS), commonly known as blue ear disease, is a contact infectious disease caused by a virus, mainly affecting the reproduction and respiratory system of pigs. The pathogen of the disease is the porcine reproductive and respiratory syndrome virus (PRRSV), which is a single-stranded RNA virus with an envelope, and has the characteristics of high morbidity and mortality. The typical symptoms include: adult sows will have reproductive disorders such as abortion, premature birth, and stillbirth, and piglets will show abnormal respiratory systems.

[0003] Currently, vaccination is mainly used for the prevention and control of PRRSV, but due to the high genetic diversity of the virus, the cross-protection effect of the vaccine is limited, and it is difficult to achieve complete prevention and control. The disease resistance of pigs is a low heritability trait, and the progress of conventional breeding is slow. Recent scientific research has confirmed that the CD163 protein is a key molecule for PRRSV to successfully invade host cells. PRRSV virus mainly invades through the CD163 receptor on the surface of host macrophages, and the SRCR5 domain is the key region for mediating infection. Knocking out the CD163 gene of pigs using gene editing technology, especially targeting the virus binding domain, can make pigs resistant to PRRSV infection. Therefore, this strategy provides a breakthrough solution for genetically enhancing the disease resistance of pig populations and breeding new disease-resistant varieties.

[0004] Currently, the CRISPR / Cas9-mediated global knockout of SRCR5 is widely used to obtain PRRSV-resistant pigs. However, a study showed that CD163-knockout mice had a significantly lower survival rate and exacerbated inflammatory response when challenged with lipopolysaccharide (LPS) and sepsis, highlighting the key role of CD163 in regulating the inflammatory process. Specifically, CD163-deficient mice had a significantly lower survival rate after LPS injection, mainly due to enhanced inflammatory response and exacerbated endotoxin shock. In addition, these knockout mice showed higher susceptibility to pathogens such as Staphylococcus aureus, further confirming the importance of CD163 in antibacterial defense, as its absence would weaken the body's resistance to bacterial infection. Although the global knockout method can effectively block PRRSV infection, this strategy would also result in the complete loss of CD163's core physiological function as a scavenger receptor, potentially interfering with the host's immune balance, anti-infection ability, and overall health status. Based on the results of the mouse experiments, it can be reasonably speculated that this knockout strategy may also significantly increase the risk of secondary bacterial infection in pigs.Specifically, CD163 not only serves as the invasion receptor of PRRSV virus (Calvert, J. G., Slade, D. E., Shields, S. L., Jolie, R., Mannan, R. M., Ankenbauer, R. G., & Welch, S. K. (2007). CD163 expression confers susceptibility to porcine reproductive and respiratory syndrome viruses. Journal of virology, 81(14), 7371-7379.), but also participates in the process of immune regulation and inflammation regulation (Etzerodt, A., and Moestrup, S. K. (2013). CD163 and inflammation: biological, diagnostic, and therapeutic aspects. Antioxidants & redox signaling, 18(17), 2352-2363.), and its most important biological function is to specifically bind and clear hemoglobin-haptoglobin complex (Hb-Hp) in blood, thereby inhibiting the oxidative damage and pro-inflammatory factor release induced by free Hb (Kristiansen, M., Graversen, J. H., Jacobsen, C., Sonne, O., Hoffman, H. J., Law, S. K., & Moestrup, S. K. (2001). Identification of the haemoglobin scavenger receptor. Nature, 409(6817), 198-201.). If this clearance mechanism fails, the accumulated free Hb not only promotes bacterial growth and virulence expression, but also amplifies the inflammatory cascade, further reducing the resistance of pigs to secondary infection.In addition, CD163 protein is also associated with the pathways of arthritis, coronary arteriosclerosis and other diseases, and its knockout may increase the risk of occurrence of these chronic inflammatory diseases (Aristoteli, L. P., Moller, H. J., Bailey, B., Moestrup, S. K., & Kritharides, L. (2006). The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis, 184(2), 342-347.), thereby amplifying the overall health risks. In summary, these evidences suggest that it is extremely important to retain the normal biological function of CD163 while knocking it out to resist PRRSV, which requires the development of more precise editing strategies, such as domain-specific knockout or conditional knockout, to minimize the negative impact on host physiology and balance virus resistance and immune homeostasis.

[0005] To solve the limitations of global knockout, some studies attempt to balance resistance and physiological function retention by precisely deleting part of the SRCR5 domain. For example, editing a specific region of the SRCR5 domain can achieve resistance to PRRSV while basically maintaining the scavenging function of CD163. However, this method often involves the deletion of a large fragment, which may cause potential damage to genomic stability and trigger unknown toxic side effects in subsequent generations, such as affecting the overall health or immune response of pigs. In addition, existing gene editing strategies rely on non-homologous end joining (NHEJ) repair pathways, resulting in high randomness of editing results and limiting the precision and controllability of editing.

[0006] Therefore, in the face of the challenge of how to balance the precision of disease resistance editing, the retention of CD163 physiological function and the minimization of toxic side effects, it is necessary to seek new sites in the SRCR5 domain on the basis of previous studies, which can effectively resist PRRSV, maintain the normal biological function of CD163 and reduce potential toxic side effects on pigs. SUMMARY

[0007] In order to overcome the deficiencies and shortcomings of the prior art, the primary purpose of the present application is to provide an application of CD163 SRCR5 domain receptor binding pentamer in preparing a reagent for constructing PRRSV-resistant gene-edited pigs.

[0008] Another purpose of the present application is to provide a sgRNA targeting the receptor binding pentamer.

[0009] Still another object of the present application is to provide a method for preparing anti-PRRSV gene edited cells.

[0010] A fourth object of the present application is to provide a method for constructing anti-PRRSV gene edited pigs based on CRISPR / Cas9 homologous recombination.

[0011] The object of the present application is achieved by the following technical solutions.

[0012] The CD163 SRCR5 domain receptor binding pentamer is located in the SRCR5 domain of the CD163 gene, and its amino acid sequence is Ala-His-Phe-Gly-Glu.

[0013] The CD163 SRCR5 domain receptor binding pentamer is formed by the adjacent beta-fold hydrophilic surface ring-shaped region of alanine-histidine-phenylalanine-glycine-glutamic acid (Ala-His-Phe-Gly-Glu), that is, a continuous arrangement of five amino acid virus receptor binding bodies containing a specific combination of aromatic residues, acidic residues and small molecular aliphatic residues.

[0014] The nucleotide sequence encoding the CD163 SRCR5 domain receptor binding pentamer is GCTCACTTTGGAGAA.

[0015] An sgRNA targeting the CD163 SRCR5 domain receptor binding pentamer, whose nucleotide sequence is shown in SEQ ID NO: 3.

[0016] An sgRNA targeting the CD163 SRCR5 domain receptor binding pentamer is prepared by the following method:

[0017] (1) Based on the above-mentioned sgRNA targeting the CD163 SRCR5 domain receptor binding pentamer, a single-stranded oligonucleotide corresponding to its complementary pairing is designed and synthesized, and annealing is performed to form a double-stranded;

[0018] (2) The annealed double-stranded obtained in step (1) is connected with the vector to obtain an sgRNA expression vector of the CRISPR system targeting the receptor binding pentamer.

[0019] The nucleotide sequence of the single-stranded oligonucleotide in step (1) is preferably shown in SEQ ID NO: 4-5, respectively.

[0020] The vector in step (2) is preferably a PX-330 vector.

[0021] The annealed double strand in step (2) is preferably connected to the PX-330 vector through the Bbs I restriction enzyme site to obtain the sgRNA expression vector CD163-sgRNA-PX330 of the CRISPR system targeting the receptor binding pentamer of the CD163 SRCR5 domain.

[0022] The CRISPR / Cas9 system targeting the receptor binding pentamer of the CD163 SRCR5 domain comprises the sgRNA expression vector targeting the receptor binding pentamer of the CD163 SRCR5 domain and the donor plasmid comprising the homologous repair template, and the system can accurately recognize the target gene by homologous recombination and realize the knockout of Ala-His-Phe-Gly-Glu, and can efficiently screen and obtain the monoclonal cells stably expressing the vector.

[0023] The donor plasmid is prepared by the following method:

[0024] (1) The homologous arm template with a total length of 600-1000 bp is designed and synthesized based on the deletion region of the receptor binding pentamer of the CD163 SRCR5 domain as the center and 300-500 bp of the left and right homologous arms;

[0025] (2) The homologous arm template obtained in step (1) is connected to the vector to obtain the donor plasmid comprising the homologous repair template.

[0026] The nucleotide sequence of the homologous arm template in step (1) is preferably as shown in SEQ ID NO: 6.

[0027] The vector in step (2) is preferably pcDNA3.1(+).

[0028] The homologous arm template in step (2) is preferably connected to the vector pcDNA3.1(+) through the Not I and Xho I restriction enzyme sites to obtain the donor plasmid (pcDNA3.1-donor-ΔAla-His-Phe-Gly-Glu) comprising the homologous repair template.

[0029] A preparation method of an anti-PRRSV gene editing cell comprises the following steps:

[0030] (1) The sgRNA expression vector (CD163-sgRNA-PX330) of the CRISPR / Cas9 system targeting the receptor binding pentamer of the CD163 SRCR5 domain and the donor plasmid (pcDNA3.1-donor-ΔAla-His-Phe-Gly-Glu) are co-transfected into porcine fetal fibroblasts by electroporation;

[0031] (2) After transfection, pressure screening is carried out using a screening medium containing G418, and positive porcine fetal fibroblasts of CD163 SRCR5 domain receptor binding pentatope double allelic deletion type are obtained through identification.

[0032] The porcine fetal fibroblasts in step (1) can be 30-day-old porcine fetal fibroblasts.

[0033] The specific operation of the pressure screening in step (2) is as follows:

[0034] The transfected cells are subcultured at a low density, and are cultured in a screening medium containing G418 for 7 days; then, the medium is replaced once, and the cells are cultured for another 8 days.

[0035] The concentration of G418 in the screening medium is preferably 500-800 μg / mL.

[0036] The identification in step (2) is preferably verification of homozygous deletion of ΔAla-His-Phe-Gly-Glu through PCR amplification and sequencing.

[0037] The primers for PCR amplification are preferably Primer-F and Primer-R, and the nucleotide sequences thereof are shown in SEQ ID NO: 7-8, respectively.

[0038] A method for constructing an anti-PRRSV gene edited pig (CD163-ΔAla-His-Phe-Gly-Glu truncated gene edited pig) based on CRISPR / Cas9 homologous recombination, comprising the following steps:

[0039] (1) The anti-PRRSV gene edited cell is used as a nuclear donor cell, is injected into a de-nucleated in-vitro matured porcine oocyte, and is subjected to somatic cell nuclear transfer cloning to obtain a reconstructed cloned embryo;

[0040] (2) 200-250 reconstructed cloned embryos obtained in step (1) are transplanted into the uterine horn of a progestational surrogate sow, and the cloned pig is fed to birth through a conventional method, so that a piglet without integration of an exogenous gene verified through whole genome sequencing is obtained, that is, the anti-PRRSV gene edited pig.

[0041] The technical principle of the application is as follows:

[0042] The anti-PRRSV ability of pigs belongs to a low to medium heritability trait, and the slow genetic progress and lack of high resistance germplasm resources make it difficult for traditional breeding to break through the disease resistance bottleneck. Based on the above background, the present application provides a method that can simultaneously consider disease resistance editing accuracy and physiological function. The present application finds that the receptor binding pentamer is an alanine-histidine-phenylalanine-glycine-glutamic acid (Ala-His-Phe-Gly-Glu) located in the SRCR5 domain of the CD163 gene, which is a continuous arrangement of five amino acid virus receptor binders containing a specific combination of aromatic residues, acidic residues and small molecular aliphatic residues, referred to as receptor binding pentamer, which is a key site for virus binding. Through CRISPR / Cas9 homologous recombination technology, precise disease resistance editing is realized under the premise of preserving the physiological function of CD163, and a new type of CD163 truncated gene edited pig is prepared, which has effective resistance to the Chinese JXA1 strain, providing new breeding materials for the pig industry that can be directly used for anti-PRRSV breeding.

[0043] The present application has the following advantages and effects relative to the prior art:

[0044] (1) The present application first finds that the five amino acid virus receptor binder Ala-His-Phe-Gly-Glu in the hydrophilic surface loop region formed by adjacent beta-folds in the CD163 protein, which is located in the SRCR5 domain of CD163, can be used as a new target for constructing anti-PRRSV gene edited pigs.

[0045] (2) In order to realize the unity of anti-PRRSV precision and CD163 physiological function, the present application uses CRISPR / Cas9 homologous recombination technology to design specific sgRNA and homologous repair templates for the receptor binding pentamer in the SRCR5 domain of the pig CD163 gene, and realizes the precise knockout of the alanine-histidine-phenylalanine-glycine-glutamic acid (Ala-His-Phe-Gly-Glu) receptor binding pentamer in pig fetal fibroblasts, forming a CD163 molecule that retains the main structure and only knocks out the alanine-histidine-phenylalanine-glycine-glutamic acid (Ala-His-Phe-Gly-Glu) receptor binding pentamer in the SRCR5 domain, which maximally retains the function of the CD163 scavenger receptor, causes less damage to the genome and reduces toxic side effects.

[0046] (3) The CD163-ΔAla-His-Phe-Gly-Glu truncated gene edited pig against PRRSV obtained by the application has smaller and more accurate genome damage compared to other editing types, and has the advantages of precision of disease resistance editing and normal biological function of CD163, without causing secondary bacterial infection, without additional burden and influence on the health of pigs, without integration of exogenous genes, and can pass the biosafety evaluation, which is beneficial to the industrialization and application of the pig.

[0047] (4) The gene edited pig obtained by the method for constructing a PRRSV-resistant gene edited pig based on CRISPR / Cas9 homologous recombination has a high survival rate (number of live piglets / total number of piglets), reaches 42.8%, a low pre-weaning mortality rate (0%), and a high survival rate during lactation (100%), has significant disease resistance and normal growth and development compared to a wild type of the same breed, and provides a new breeding material for pig industry that can be directly used for PRRSV resistance. BRIEF DESCRIPTION OF DRAWINGS

[0048] Figure 1 is a comparison diagram of three-dimensional structures of wild type and mutant of pig CD163 SRCR5 domain; wherein, A: PAE heat map shows low residue position error (0-30 Å, mainly green), supporting the structural reliability of SRCR5 domain and adjacent interface (RMSD between SRCR4-SRCR5 and SRCR5-SRCR6<1.1 Å); B: highlights β4 and β5 strands (marked as red rings, indicating the affected area); C: AlphaFold3-predicted three-dimensional structure of mutant pig CD163 protein (full length 1110 aa) shows high folding similarity with wild type (CA-RMSD<2 Å, average pLDDT>78), and a cavity is missing at the β4-β5 loop (residues 530-534, white surface); this visualization focuses on structural changes and does not directly depict the electrostatic potential surface (calculated by APBS as +5~+7 kT / e for wild type and-1~+1 kT / e for mutant); see Example 1 for analysis of electrostatic energy and binding energy (ΔG_ele≈-12.4 kcal / mol).

[0049] Figure 2 is a schematic diagram of gene editing and homologous recombination of the pig CD163 gene receptor binding pentamer region.

[0050] Figure 3 is a result analysis diagram of lung CD163 protein expression level of CD163-ΔAla-His-Phe-Gly-Glu gene edited pig.

[0051] Figure 4are the sequencing peak maps of positive monoclonal cells and gene edited piglets; wherein, A: sequencing peak map of positive monoclonal cells, B: sequencing peak map of surviving piglets, C: sequencing peak map of dead piglets.

[0052] Figure 5 are the result analysis graphs of rectal temperature, survival curve, and PRRSV content and antibody level in serum of wild type and ΔAla-His-Phe-Gly-Glu Large White piglets after challenge; wherein, the sample number of wild type group is 9; the sample number of knock-out receptor binding pentamer group (ΔAla-His-Phe-Gly-Glu) is 6; the sample number of blank control group is 5; A: rectal temperature of three groups of pigs after infection with PRRSV, body temperature above 40℃ is regarded as fever; B: survival curve of three groups of pigs after infection with PRRSV; C: average value of anti-PRRSV antibody in serum of three groups of pigs, the horizontal line is the critical value (0.4) of positive determination; D: average concentration of PRRSV nucleic acid in serum of three groups of pigs.

[0053] Figure 6 are the sequencing peak maps of positive monoclonal cells and gene edited piglets of Comparative Example 1; wherein, A: sequencing peak map of positive monoclonal cells, B: sequencing peak map of dead piglets. DETAILED DESCRIPTION

[0054] The application will be described in further detail below with reference to the embodiments and drawings, but the embodiments of the application are not limited thereto.

[0055] Example 1

[0056] 1. In order to evaluate the effect of deleting the receptor binding pentamer (located at the 530-534th amino acid in the full length, the sequence is located at the β4-β5 Loop connection region, which is the core recognition epitope of PRRSV GP4 / GP2 complex binding) in the SRCR5 domain of pig CD163 protein on the function of the receptor, the present application precisely deletes the 5 amino acids at the 530-534th position, the mutant has a full length of 1110 aa, retains the overall skeleton integrity of the SRCR5 domain, and only destroys the virus binding site.

[0057] 2. The three-dimensional structure of wild type pig CD163 protein (UniProt ID: Q2VL90, PDB: 5HRJ, full length 1115 aa) and mutant pig CD163 protein with deleted receptor binding pentamer was predicted by AlphaFold3 (https: / / alphafoldserver.com) respectively.

[0058] 3. The atomic-level vacuum electrostatic potential (range -7 kT / e to +7 kT / e) of wild-type and mutant porcine CD163 proteins were calculated using PyMOL with the APBS Electrostatics plugin (parameters: pH 7.4, ionic strength 150 mM NaCl, protein dielectric constant 2.0, solvent dielectric constant 78.5, grid spacing 0.5 Å).

[0059] The three-dimensional structure shows: the resulting model pLDDT average > 78, local CA-RMSD < 2 Å, the overall folding of the mutant porcine CD163 protein after deleting the receptor binding pentad is highly coincident with that of the wild-type porcine CD163 protein ( Figure 1 ).

[0060] The calculation results show that: the receptor binding pentad in the SRCR5 domain of the wild-type CD163 protein forms a highly localized strong positive potential cluster (+5 ~ +7 kT / e), mainly contributed by the Arg / Lys residues around His509, Phe510, Gly512, as well as the β4 strand (residues about 500-508) and β5 strand (residues about 514-522). This positive potential point forms a very strong interatomic electrostatic attraction with the negative region (Asp / Glu enrichment) on the PRRSV envelope protein complex (GP2a / GP4 heterodimer) (the electrostatic term ΔG_ele in the binding free energy contribution is approximately -12.4 kcal / mol, significantly higher than the hydrogen bond and hydrophobic contributions), which is the decisive step for virus attachment and triggering CD163 unfolding. After precisely deleting the receptor binding pentad, this positive potential point completely disappears, the corresponding region turns into neutral to weak negative potential (-1 ~ +1 kT / e), the electrostatic interaction energy is close to 0 kcal / mol·e, and the spatial rearrangement of the original positive residues caused by the collapse of the β4-β5 Loop further shields any residual attraction; at the same time, the overall skeleton of the SRCR5 domain and the salt bridge network between adjacent domains (especially the SRCR4-SRCR5, SRCR5-SRCR6 interface) are not disturbed, and the conformational stability of the extracellular segment of the protein is not significantly different from the wild-type (RMSD < 1.1 Å).

[0061] The amino acid sequence of CD163 protein (SEQ ID NO: 1):

[0062] MDKLRMVLHENSGSADFRRCSAHLSSFTFAVVAVLSACLVTSSLGGKDKELRLTGGENKCSGRVEVKVQEEWGTVCNNGWDMDVVSVVCRQLGCPTAIKATGWANFSAGSGRIWMDHVSCRGNESALWDCKHDGWGKHNCTHQQDAGVTCSDGSDLEMGLVNGGNRCLGRIEVKFQGRWGTVCDDNFNINHASVVCKQLECGSAVSFSGSANFGEGSGPIWFDDLVCNGNESALWNCKHEGWGKHNCDHAEDAGVICLNGADLKLRVVDGVTECSGRLEVKFQGEWGTICDDGWDSDDAAVACKQLGCPTAVTAIGRVNASEGTGHIWLDSVSCHGHESALWQCRHHEWGKHYCNHDEDAGVTCSDGSDLELRLKGGGSHCAGTVEVEIQKLVGKVCDRSWGLKEADVVCRQLGCGSALKTSYQVYSKTKATNTWLFVSSCNGNETSLWDCKNWQWGGLSCDHYDEAKITCSA HRKPRLVGGDIPCSGRVEVQHGDTWGTVCDSDFSLEAASVLCRELQCGTVVSLLGGAH FGEGSGQIWAEEFQCEGHESHLSLCPVAPRPDGTCSHSRDVGVVCS RYTQIRLVNGKTPCEGRVELNILGSWGSLCNSHWDMEDAHVLCQQLKCGVALSIPGGAPFGKGSEQVWRHMFHCTGTEKHMGDCSVTALGASLCSSGQVASVICSGNQSQTLSPCNSSSSDPSSSIISEENGVACIGSGQLRLVDGGGRCAGRVEVYHEGSWGTICDDSWDLNDAHVVCKQLSCGWAINATGS AHFGEGTGPIWLDEINCNGKESHIWQCHSHGWGRHNCRHKEDAGVICSEFMSLRLISENSRETCAGRLEVFYNGAWGSVGRNSMSPATVGVVCRQLGCADRGDISPASSDKTVSRHMWVDNVQCPKGPDTLWQCPSSPWKKRLASPSEETWITCANKIRLQEGNTNCSGRVEIWYGGSWGTVCDDSWDLEDAQVVCRQLGCGSALEAGKEAAFGQGTGPIWLNEVKCKGNETSLWDCPARSWGHSDCGHKEDAAVTCSEIAKSRESLHATGRSSFVALAIFGVILLACLIAFLIWTQKRRQRQRLSVFSGGENSVHQIQYREMNSCLKADETDMLNPSGDHSEVQ

[0063] Note: The first horizontal line part is the seventh exon (SRCR5 domain), the first horizontal line part contains the receptor binding pentad, and the second horizontal line part is another receptor binding pentad.

[0064] The nucleotide sequence corresponding to the seventh exon (SRCR5 domain) (SEQ ID NO: 2):

[0065] CACAGGAAACCCAGGCTGGTTGGAGGGGACATTCCCTGC TCTGGTCGTGTTGAAGTACAACATGGAGAC ACGTGG GGCACCGTCTGTGATTCTGACTTCTCTCTGGAGGCGGCCAGCGTGCTGTGCAGGGAACTACAGTGCGGCACTGTGGTTTCCCTCCTGGGGGGA GCTCACTTTGGAGAA GGAAGTGGACAGATCTGGGCTGAAGAAT TCCAGTGTGAGG GGCACGAGTCCCACCTTTCACTCTGCCCAGTAGCACCCCGCCCTGACGGGACATGTAGCCACAGC AGGGACGTCGGCGTAGTCTGCTCA

[0066] Note: The first horizontal line part is the ligand binding pocket (Ligand binding pocket, LBP), the second horizontal line part is the receptor binding pentad, and the third horizontal line part is Loop 5-6.

[0067] Example 2 CRISPR system targeting the receptor binding pentad

[0068] 1. Construction of sgRNA expression vector

[0069] (1) According to the full sequence information of pig CD163 gene (Accession No: NC_010447.5) in NCBI database, a sgRNA target sequence was designed according to the receptor binding pentamer sequence of CD163 SRCR5 domain.

[0070] (2) According to the sgRNA target sequence designed in step (1), complementary single-stranded oligonucleotides (sgRNA-F and sgRNA-R) were synthesized, annealed according to the conventional method, and double-stranded was formed (Table 1).

[0071] Table 1 sgRNA target sequence and single-stranded oligonucleotide targeting receptor binding pentamer

[0072]

[0073] Note: AGG is PAM sequence.

[0074] (3) According to the conventional method, Bbs I restriction endonuclease (Thermo, Catalog No: ER1011) was used to linearize PX330 plasmid (Addgene plasmid, Catalog No: 42230); then the linearized PX330 plasmid and the annealed double-stranded product obtained in step (2) were ligated by T4 ligase (Takara, Catalog No: 2011A) at 16°C overnight to obtain the ligation product.

[0075] (4) The ligation product obtained in step (3) was transformed into DH5a competent cells, and the positive bacteria were selected and cultured. The positive bacteria were extracted, and the plasmid was named CD163-sgRNA-PX330. The sgRNA primer was confirmed to be correctly connected by gene sequencing, and the plasmid was stored in a refrigerator at -20°C. The plasmid was used for cell transfection.

[0076] 2. Construction of donor plasmid

[0077] (1) A homologous arm of 800 bp in total length was synthesized with the receptor binding pentamer deletion region as the center and 400 bp homologous arms on its upstream and downstream (SEQ ID NO: 6), and Not I and Xho I restriction sites (Thermo, FD0593, ER0692) were introduced at 5' and 3' ends. Not I and Xho I were used to double digest pcDNA3.1 (+) (Addgene plasmid, Catalog No: V790-20); the homologous arm sequence with Not I and Xho I restriction sites and the digested pcDNA3.1 (+) vector were ligated by T4 ligase at 16°C overnight to obtain the ligation product.

[0078] Nucleotide sequence of L-homologous arm and R-homologous arm (SEQ ID NO: 6):

[0079] CAAAGGAAAGAGAAAGCATGCTCCAAGAATTATGGGTTCCAGAAGGCAAAGTCCCAGAATTGTCTCCAG GGAAGGACAGGGAGGTCTAGAATCGGCTAAGCCCACTGTAGGCAGAAAAACCAAGAGGCATGAATGGCTTCCCTTTC TCACTTTTCACTCTCTGGCTTACTCCTATCATGAAGGAAAATATTGGAATCATATTCTCCCTCACCGAAATGCTATT TTTTCAGCCCACAGGAAACCCAGGCTGGTTGGAGGGGACATTCCCTGCTCTGGTCGTGTTGAAGTACAACATGGAGA CACGTGGGGCACCGTCTGTGATTCTGACTTCTCTCTGGAGGCGGCCAGCGTGCTGTGCAGGGAACTACAGTGCGGCA CTGTGGTTTCCCTCCTGGGGGGA GGAAGTGGACAGATCTGGGCTGAAGAATTCCAGTGTGAGGGGCACGAGTCCCACCTTTCACTCTGCCCAGTAGCACCCCGCCCTGACGGGACATGTAGCCACAGCAGGGACGTCGGCGTAGTCTGCTCAAGTGAGACCCAGGGAATGTGTTCACTTTGTTCCCATGCCATGAAGAGGGTAGGGTTAGGTAGTCACAGACATCTTTTTAAAGCCCTGTCTCCTTCCAGGATACACACAAATCCGCTTGGTGAATGGCAAGACCCCATGTGAAGGAAGAGTGGAGCTCAACATTCTTGGGTCCTGGGGGTCCCTCTGCAACTCTCACTGGGACATGGAAGATGCCCATGTTTTATGCCAGCAGCTTAAATGTGGAGTTGCCCTTTCTATCCCGGGAGGAGCA

[0080] Note: The horizontal line part is L-homologous arm, and the remaining part is R-homologous arm.

[0081] (2) Transform the ligation product obtained in step (1) into DH5α competent cells, plate and screen the culture, pick positive bacteria for expansion culture, extract the plasmid from the positive bacteria, and name the plasmid as pcDNA3.1-donor-ΔAla-His-Phe-Gly-Glu. After confirming that the homologous arm repair template is connected without error and without base change through gene sequencing, store the plasmid in a refrigerator at -20°C, and use it for cell transfection. Among them, the upstream primer of plasmid identification is located outside the left homologous arm, and the downstream primer is located at the end of the right homologous arm (Table 2).

[0082] Table 2 Identification primer

[0083]

[0084] Example 3 Preparation of gene edited cells

[0085] 1. Primary isolation and preparation of porcine fetal fibroblasts

[0086] In the Wenshi pig farm in Qingyuan City of Guangdong Province, a pregnant W65 white sow with excellent production performance was selected for slaughter, and its uterus was quickly removed and transported to the National Pig Breeding Engineering Technology Research Center of South China Agricultural University at 4°C for primary separation and preparation of porcine fetal fibroblasts (PFFs). The specific steps are as follows:

[0087] ①Fetal tissue was isolated from the uterus of a sow at 30 days of pregnancy, and then the fetus was rinsed with phosphate buffered saline (PBS) containing 100 U / mL penicillin and 100 μg / mL streptomycin 3 times to remove surface contaminants. Then, the head, limbs, internal organs and tail of the fetus were removed, and only the skin and muscle tissue of the trunk were retained. The remaining tissue was cut into small pieces of 1-2 mm³.

[0088] ②Collagenase lysis solution (40.75 mL 1×Gluta Max DMEM medium (Gibco, Catalog No: 10569-010), 7.5 mL fetal bovine serum (FBS, Gibco), 32 mg type IV collagenase (Gibco, Catalog No: 17104019), 1 mL penicillin-streptomycin (PS) solution (Gibco, Catalog No: 15140122)) was added to the tissue pieces cut in step ①, and digested at 38°C in a 5% CO2 incubator for 4-6 h.

[0089] ③After digestion, the cell suspension was collected with a Pasteur pipette, centrifuged at 1000 rpm for 5 min, and the supernatant was discarded. Then the cell pellet was resuspended with FBS, progressively frozen to -80°C, and finally transferred to a liquid nitrogen tank for long-term storage, which is the primary PFFs cells.

[0090] ④The PFFs cells recovered after primary separation were placed in 1× Gluta Max DMEM complete medium containing 15% FBS, and cultured in a 38°C, 5% CO2 incubator. When the cell density reached 80-90%, the cells were digested and collected for use.

[0091] 2. Blind screening

[0092] ①Take 1×10 6 PFFs cells, according to the Bio-Rad electroporation buffer instructions, take 5 μg of plasmid CD163-sgRNA-PX330 obtained in Example 1 for transfection, use Bio-Rad electroporator square wave program, electric conversion parameters: voltage 200 V, pulse length 20 ms, pulse interval 2 s for electroporation.

[0093] ② After transfection, the cells were plated at low density, i.e. about 2-3 cells per 40x microscopic field were plated in 10 cm dishes, a total of 20 dishes. Culture with 1x Gluta Max DMEM containing 15% FBS was performed, and the whole culture process lasted for 10 days, during which the medium was changed at day 5. After 10 days of culture, the surviving single colonies were picked and cultured in 48-well plates.

[0094] 3. Homologous recombination method

[0095] ① 1x10 6 PFFs cells were taken, and plasmid CD163-sgRNA-PX330 and plasmid pcDNA3.1-donor-ΔAla-His-Phe-Gly-Glu obtained in Example 1 were co-transfected according to the Bio-Rad electroporation buffer instruction, and the Bio-Rad electroporator square wave program was selected, and the electroporation parameters were: voltage 200 V, pulse length 20 ms, and pulse interval 2 s.

[0096] ② After transfection, the cells were plated at low density, i.e. about 20-30 cells per 40x microscopic field were plated in 10 cm dishes, a total of 20 dishes. Subsequently, G418 screening culture was performed, and the whole screening culture process lasted for 15 days. The specific method is as follows: first, the screening medium containing 500 μg / mL G418 was added to the culture dishes for culture, and after observing the number and state of single colonies under a microscope, the results showed that the number of single colonies was more than expected and the state was good as the culture time increased. The screening medium containing 800 μg / mL G418 was changed on the 7th day after observing the dynamics of the cells, and the culture was continued for 8 days. The screening medium containing G418 was prepared by the following method: G418 sulfate solution (Shanghai Genechem Co., Ltd., item number: B540723-0005) was added to 1x Gluta Max DMEM medium (Gibco, item number: 10569-010) to obtain. After 15 days of screening culture, the surviving single colonies were picked and cultured in 48-well plates.

[0097] 4. After the single colonies in step 2 or step 3 were fully grown, a small amount of cell suspension was taken by trypsin digestion, centrifuged at 1000 rpm for 5 min, and after the supernatant was discarded, 5 μL lysis buffer was added to resuspend the cells, and the cells were lysed at 56℃ for 1 h, and the proteinase K was inactivated at 95℃ for 10 min. The 1 L lysis buffer contains the following components: 5 μL NP-40 (Boyotime, item number: P0013F), 200 μL proteinase K (Beyotime, item number: ST532), and 800 μL deionized water.

[0098] 5. After the completion of lysis inactivation, 2 μL of cell lysate was taken as a template to use Primer-F and Primer-R (Table 2) for PCR amplification and sequencing to screen positive clones for successful knockout of the receptor binding pentad, and obtain CD163 SRCR5 domain receptor binding pentad double allele (homozygous) deletion type positive Large White pig fetal fibroblasts. The remaining cells identified as positive were transferred to a 24-well plate for continued culture and expansion. After the positive cells covered the 24-well plate, they could be used as donor cells for somatic cell nuclear transfer (SCNT).

[0099] The PCR sequencing results are shown in Tables 3 and 4. The total number of 5 single colonies from 10 cm dishes at the 15th day of G418 screening was 50, and the single colonies obtained by PCR sequencing and comparison were all edited, of which the majority were insertion type edits, with an editing efficiency of 100%, and the number of single colonies edited to the receptor binding pentad was 2, with a double allele editing efficiency of 4%. The efficiency of double allele editing by blind screening, i.e., without using homologous recombination technology, but only using one sgRNA expression vector for electroporation, was much lower than that of homologous recombination. The blind screening single colony PCR sequencing results showed that the editing efficiency was much lower than that of homologous recombination, and only one single allele edited single colony was screened in the screening process, with an efficiency of 0.3%, which means that there is a one in 100,000 chance of screening a double allele edited single colony. It can be seen that the use of homologous recombination technology to edit the receptor binding pentad is highly efficient.

[0100] Table 3 Homologous recombination method single colony genotype identification

[0101]

[0102] Table 4 Blind screening single colony genotype identification

[0103]

[0104] Example 4 Preparation of CD163-ΔAla-His-Phe-Gly-Glu truncated gene edited pig

[0105] 1. The CD163 SRCR5 domain receptor binding pentad homozygous deletion type positive single colony cells (5-28# and 5-41#, Figure 4In the middle A), as a nuclear transfer donor cell, a pig oocyte is used as a recipient cell, the nuclear transfer donor cell is transplanted into the enucleated oocyte, and the specific method is as follows: after the position of the in vitro matured MII stage oocyte nucleus of a W65 white pig (from Wenshi Dongcheng Farm) is determined under a fluorescence microscope, the oocyte nucleus and the first polar body are accurately removed by using a micromanipulation needle, and a positive monoclonal obtained in Example 2 which is homozygous deletion type of the receptor binding pentatope is injected into the perivitelline space to obtain a reconstructed oocyte.

[0106] 2. The reconstructed oocytes are placed in a fusion tank coated with activation solution (purchased) in batches, the donor cell located in the perivitelline space is perpendicular to the electrode with the axis of the recipient oocyte, and 100 V / mm, 80 μs, 2 times pulse direct current is used for inducing fusion and activation to obtain a reconstructed cloned embryo.

[0107] 3. A synchronized estrus surrogate Wenshi W65 white sow is selected, the uterus is exposed by surgery, and the reconstructed cloned embryo obtained in step 2 is input into the end of the oviduct through the uterine horn, wherein 200-250 reconstructed cloned embryos are transplanted into each surrogate sow. The pregnant state and health condition of the surrogate sow are regularly monitored until the cloned pig is born, and the birth of the cloned pig is observed according to a conventional method.

[0108] 4. The ear skin tissue of the cloned pig in step 3 is collected, DNA is extracted, and then PCR amplification and sequencing are performed by using Primer-F and Primer-R (Table 2) to identify whether it is homozygous deletion of the receptor binding pentatope.

[0109] 5. The expression level of CD163 protein is detected by Western blot, wherein the CD163 primary antibody is Mouse antiPig CD163 Monoclonal Antibody (BioRad, item number: MCA2311GA), the secondary antibody is HRP-conjugated anti-mouse IgG (Ptg, item number: SA00001-1), and the internal reference is β-Tubulin Monoclonal antibody (Ptg, item number: 66240-1-Ig).

[0110] The birth of the cloned pig and the gene editing condition are shown in Table 5 and Table 6, and the sequencing chart result is shown in Figure 4 Table 6. As shown in Table, the efficiency of gene editing by the sgRNA and the Donor plasmid designed in the application through the homologous recombination technology reaches 100%, and the editing efficiency of double alleles is as high as more than 80%. The Western blot result is shown in Figure 3 Table 3, and the expression level of CD163 gene in the normal control pig has no difference, which indicates that the CD163-ΔAla-His-Phe-Gly-Glu truncated gene edited pig is successfully prepared.

[0111] Table 5 Gene editing of surviving piglets

[0112]

[0113] Note: Calculation method of editing efficiency (take Table 5 as an example): the total number of gene editing individuals of 5-28# and 5-41# is 4+2=6, among which, there is 1 pig with single allele editing, i.e. 1 / 6, and the remaining 5 pigs are double allele editing, i.e. 5 / 6.

[0114] Table 6 Gene editing of dead piglets

[0115]

[0116] Example 5 Anti-disease test of CD163-ΔAla-His-Phe-Gly-Glu truncated gene edited pigs against JXA1

[0117] Take 35-day-old 6 pigs of Example 3 obtained by receptor binding pentaplex knockout (ΔAla-His-Phe-Gly-Glu group), 9 wild type large white pigs (control group) and 5 wild type large white pigs (blank control group), and the above piglets are double negative by antigen antibody detection. Challenge with 2 mL of JXA1 strain (the strain is a gift from the Livestock and Poultry Disease Prevention and Control Research Room of Guangdong Wen's Research Institute, and the titer is 5x10 4 TCID 50 / mL), and then continuously monitored for 21 days. Baseline blood samples were collected before challenge; clinical symptoms (body temperature, spirit, feed intake, etc.) and death were recorded daily after challenge; blood samples were collected on days 3, 7, 10, 14, and 21 after challenge to isolate serum. First, the virus in the serum was extracted by a virus total nucleic acid kit (Magen, catalog number: R4173-03), and then the system was prepared according to the instructions of ChamQ Universal SYBR qPCR Master Mix (Vazyme, catalog number: Q711-02) and detected by machine (Vazyme, catalog number: Q711-02) to detect the viral RNA load in serum; IDEXX blue ear PRRSV antibody kit (IDEXX Laboratories, catalog number: 99-40959) was used to detect antibody level; virus infection dynamics, pathological damage and immune response were comprehensively evaluated.

[0118] The results after 21 days of challenge are shown in Figure 5 The rectal temperature of the control group pigs was significantly increased 2 days after challenge (D2), and reached the clinical fever threshold of more than 41℃ on D4-D7, and then maintained a high temperature of more than 40℃ until the end of the experiment. The rectal temperature of the ΔAla-His-Phe-Gly-Glu group and the blank control group was always stable between 39-40℃, and no fever symptoms occurredFigure 5 A).

[0119] In terms of survival rate, the control group pigs began to die from D7, the survival rate decreased to less than 50% on D10, and all died on D14; the ΔAla-His-Phe-Gly-Glu group pigs had two pigs died of stress on D1, so that the survival rate remained 66.7% before D10, although a small amount of death occurred after D10, but the survival rate remained about 34% on D21; the blank control group had no death, and the survival rate was always 100% Figure 5 B).

[0120] The antibody reaction detection showed that the serum antibody S / P ratio of the control group pigs began to increase significantly on D7, reached a peak (about 0.7) on D10, and then gradually decreased, but was always higher than the Cut-off value for antibody positive judgment; the S / P ratio of the ΔAla-His-Phe-Gly-Glu group pigs was always lower than the Cut-off value, and no effective specific antibody reaction was produced; the blank control group had no obvious antibody change Figure 5 C).

[0121] The serum virus RNA load results showed that the control group pigs detected a high level of virus load (about 8 log 10 copies / mL) on D3, which was maintained at a high level until D14, although it decreased slightly after D14, but remained above 7 log 10 copies / mL; the virus load of the ΔAla-His-Phe-Gly-Glu group pigs was only about 6 log 10 copies / mL on D3, then slowly increased, reached about 8 log 10 copies / mL on D14, but the rising speed was significantly slower than that of the wild type group; the blank control group did not detect virus RNA throughout Figure 5 D).

[0122] In summary, it is shown that knocking out the receptor binding pentamer can significantly reduce the susceptibility and pathogenicity of pigs to JXA1 strain, and the novel truncated CD163 gene edited pig obtained based on the CRISPR / Cas9 homologous recombination technology provided by the present application can significantly improve the disease resistance to PRRSV JXA1 strain.

[0123] Comparative Example 1

[0124] A receptor binding pentatope (Ala-His-Phe-Gly-Glu) also exists in the SRCR7 domain of porcine CD163 protein, a sgRNA target sequence (Table 7) was designed for this site, referring to Example 2, the sgRNA expression vector and Donor plasmid were constructed, the corresponding single-stranded oligonucleotide is shown in Table 7, the nucleotide sequences of L-homologous arm and R-homologous arm are as follows; referring to Example 3, the corresponding gene editing cells were prepared, and referring to Example 4, the corresponding gene editing pigs were constructed, although positive monoclonal cells were obtained, the surrogate mother pigs were all aborted, and all the piglets obtained died Figure 6 ).

[0125] Table 7 sgRNA target sequence of SRCR7 domain and its single-stranded oligonucleotide

[0126]

[0127] The nucleotide sequences of L-homologous arm and R-homologous arm of SRCR7 are as follows:

[0128] TGTGGGTATCTCCGATATTTTGTATCTTCTGTGACTGAGTGGTTTGCTGTTTGCAGGGAACCAGAGTCA GACACTATCCCCGTGCAATTCATCATCCTCGGACCCATCAAGCTCTATTATTTCAGAAGAAAATGGTGTTGCCTGCA TAGGTGAGAATCAGTGACCAACCTATGAAAATGATCTCAATCCTCTGAAATGCATTTTATTCATGTTTTATTTCCTC TTTGCAGGGAGTGGTCAACTTCGCCTGGTCGATGGAGGTGGTCGTTGTGCTGGGAGAGTAGAGGTCTATCATGAGGG CTCCTGGGGCACCATCTGTGATGACAGCTGGGACCTGAATGATGCCCATGTGGTGTGCAAACAGCTAAGCTGTGGAT GGGCCATTAATGCCACTGGTTCT GGAACAGGGCCCATTTGGCTGGATGAGATAAACTGTAATGGAAAAGAATCTCATATTTGGCAATGCCACTCACATGGTTGGGGGCGGCACAATTGCAGGCATAAGGAGGATGCAGGAGTCATCTGCTCGGGTAAGTTCTGCACATCACTTCGGGTTACAGTGATTTAAGAAACAACTAAGGTGGGGCAAAGGGTAGTGAGGCATATCCATCAGAGCAAATTCCTTGAAATACGGACTCAGAGGGAACCATTGTGAGATTGAGGTTCCCAGAGGTGTGGATTTAATGAATTAGTGTTACCTCATGTACAAGGTAGTATACTACCAGAAAGATAAAAATTCAGAAGCGAGTTTGCAGCAAAACTCATAGGGAGAACTTCTTTTATAAATAATATGAAGCTGG

[0129] Note: The horizontal line part is L-homologous arm, and the remaining part is R-homologous arm.

[0130] The above embodiments are the preferred embodiments of the present application, but the embodiments of the present application are not limited to the above embodiments, and any changes, modifications, substitutions, combinations, simplifications, etc. made without departing from the spirit and principles of the present application should be equivalent replacement manners and should be included in the protection scope of the present application.

Claims

1. A use of a CD163 SRCR5 domain receptor binding pentamer in the preparation of a reagent for constructing an anti-PRRSV gene edited pig, characterized in that The CD163 SRCR5 domain receptor binding pentatope is located in the SRCR5 domain of the CD163 gene, and the amino acid sequence is Ala-His-Phe-Gly-Glu.

2. An sgRNA targeting the CD163 SRCR5 domain receptor binding pentamer, characterized in that The nucleotide sequence is shown as SEQ ID NO:

3.

3. An sgRNA expression vector targeting the CD163 SRCR5 domain receptor binding pentamer, characterized by Prepared by the following method: (1) Based on the sgRNA targeting the CD163 SRCR5 domain receptor binding pentatope, a complementary single-stranded oligonucleotide is designed and synthesized, and annealing is performed to form a double-stranded; (2) The annealed double-stranded obtained in step (1) is connected with the vector to obtain the sgRNA expression vector of the CRISPR system targeting the receptor binding pentatope.

4. The sgRNA expression vector targeting the CD163 SRCR5 domain receptor binding pentatope according to claim 3, characterized in that: The nucleotide sequence of the single-stranded oligonucleotide in step (1) is shown as SEQ ID NO: 4-5, respectively.

5. A CRISPR / Cas9 system targeting the CD163 SRCR5 domain receptor binding pentad, characterized in that The sgRNA expression vector targeting the CD163 SRCR5 domain receptor binding pentatope of claim 3 or 4 and the donor plasmid containing the homologous repair template.

6. The CRISPR / Cas9 system targeting the CD163 SRCR5 domain receptor binding pentatope according to claim 5, characterized in that: The donor plasmid is prepared by the following method: (1) Based on the deletion region of the CD163 SRCR5 domain receptor binding pentatope as the center, a homologous arm template with a total length of 600-1000 bp is designed and synthesized based on the left and right homologous arms of 300-500 bp; (2) The homologous arm template obtained in step (1) is connected to the vector to obtain the donor plasmid containing the homologous repair template.

7. The CRISPR / Cas9 system targeting the CD163 SRCR5 domain receptor binding pentatope according to claim 6, characterized in that: The nucleotide sequence of the homologous arm template in step (1) is shown as SEQ ID NO:

6.

8. A method of making an anti-PRRSV genetically edited cell, comprising The steps include: (1) The sgRNA expression vector and donor plasmid of the CRISPR / Cas9 system targeting the CD163 SRCR5 domain receptor binding pentatope according to any one of claims 5-7 are co-transfected into porcine fetal fibroblasts by electroporation; (2) After transfection, pressure screening is performed using a screening medium containing G418, and positive porcine fetal fibroblasts with double allelic deletion of the CD163 SRCR5 domain receptor binding pentatope are obtained.

9. An anti-PRRSV genetically edited cell, characterized in that Prepared by the method of claim 8.

10. A method for constructing anti-PRRSV gene edited pigs based on CRISPR / Cas9 homologous recombination, characterized in that The steps include: (1) The anti-PRRSV gene editing cell of claim 9 is used as a nucleus donor cell and injected into a de-nucleated in vitro matured porcine oocyte to perform somatic cell nuclear transfer cloning to obtain a reconstructed cloned embryo; (2) 200-250 reconstructed cloned embryos obtained in step (1) are transplanted into the uterine horn of estrus gestation sows, and the cloned pigs are fed by a conventional method until birth, to obtain piglets verified by whole genome sequencing as having no exogenous gene integration, i.e. PRRSV-resistant gene-edited pigs.

Citation Information

Patent Citations

  • Method of cloning reproductive and respiratory syndrome resisting pig

    CN104593422A

  • Targeting sgRNA for pig CD163 gene editing, modification vector, and preparation method and application thereof

    CN107177595A

  • Gene knockout carrier and method for preparing CD163 gene knockout porcine fibroblasts

    CN107354170A

  • MARC-145 cell line against porcine reproductive and respiratory syndrome and preparation method and use thereof

    WO2019119521A1